NCT01497626 - Lapatinib and Bortezomib in Patients With Advanced Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions

Advanced Solid Tumors

Interventions

DRUG

Lapatinib and bortezomib

"Lapatinib will be taken orally continuously for 28 days of each 28-day cycle, including a run-in of lapatinib alone day -7 to day 1 of cycle 1.~Bortezomib will be administered IV on days 1, 8, and 15 of each cycle. The exact doses of both drugs will be dependent on which cohort the subject is in and adverse events observed in previous cohorts."

Trial Locations (1)

20007

Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.